265 related articles for article (PubMed ID: 787654)
21. Immunotherapy of a murine colon cancer with syngeneic spleen cells, immune RNA and tumor antigen.
Fukushima M; Colmerauer ME; Nayak SK; Koziol JA; Pilch YH
Int J Cancer; 1982 Jan; 29(1):107-12. PubMed ID: 6174460
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy of a murine sarcoma using specific antitumor immune RNA.
Webster DJ; Cornacoff JB; Vallera DA; Dalmasso JP; Dodd MC; Minton JP
J Surg Oncol; 1979; 12(3):213-20. PubMed ID: 502564
[TBL] [Abstract][Full Text] [Related]
24. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
[TBL] [Abstract][Full Text] [Related]
25. In vitro induction of tumor-specific immunity. I. Parameters of activation and cytotoxic reactivity of mouse lymphoid cells immunized in vitro against syngeneic and allogeneic plasma cell tumors.
Wagner H; Röllinghoff M
J Exp Med; 1973 Jul; 138(1):1-15. PubMed ID: 4541509
[TBL] [Abstract][Full Text] [Related]
26. Passive transfer of systemic tumor immunity with cells generated in vitro by a secondary immune response to a syngeneic rat gross virus-induced lymphoma.
Bernstein ID
J Immunol; 1977 Jan; 118(1):122-8. PubMed ID: 830744
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of cancer with "immune" RNA. A preliminary report.
Pilch YH; de Kernion JB; Skinner DG; Ramming KP; Schick PM; Fritze D; Brower P; Kern DH
Am J Surg; 1976 Nov; 132(5):631-7. PubMed ID: 984310
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for cancer: an overview.
Proctor JW; Lewis MG; Mansell PW
Can J Surg; 1976 Jan; 19(1):12-9. PubMed ID: 1145
[TBL] [Abstract][Full Text] [Related]
29. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
30. Sensitization in vitro to murine myeloblastic leukemia cells by xenogeneic immune RNA.
Preisler HD; Jacobs SK
J Natl Cancer Inst; 1979 Jan; 62(1):133-7. PubMed ID: 281568
[TBL] [Abstract][Full Text] [Related]
31. Immune RNA therapy as an effective adjuvant immunotherapy after surgery: an animal model.
Aarons S; Krishnan EC; Mebust WK; Jewell WR
J Surg Oncol; 1983 May; 23(1):21-6. PubMed ID: 6188924
[TBL] [Abstract][Full Text] [Related]
32. Prevention of death from metastases by immune RNA therapy.
Wang BS; Onikul SR; Mannick JA
Science; 1978 Oct; 202(4363):59-60. PubMed ID: 694519
[TBL] [Abstract][Full Text] [Related]
33. RNA pulsed dendritic cells: an approach for cancer immunotherapy.
Garg NK; Dwivedi P; Prabha P; Tyagi RK
Vaccine; 2013 Feb; 31(8):1141-56. PubMed ID: 23306369
[TBL] [Abstract][Full Text] [Related]
34. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells.
Nair SK; Heiser A; Boczkowski D; Majumdar A; Naoe M; Lebkowski JS; Vieweg J; Gilboa E
Nat Med; 2000 Sep; 6(9):1011-7. PubMed ID: 10973321
[TBL] [Abstract][Full Text] [Related]
35. [Adoptive immunotherapy of the established S-180 ascitic tumor with the syngeneic normal splenic cells treated by the xenogeneic immune ribonucleic acid].
Chiou CY
Gaoxiong Yi Xue Ke Xue Za Zhi; 1985 Aug; 1(8):494-504. PubMed ID: 2454322
[No Abstract] [Full Text] [Related]
36. Tumor regression at an untreated site during immunotherapy of an identical distant tumor.
Schlager SI; Dray S
Proc Natl Acad Sci U S A; 1975 Sep; 72(9):3680-2. PubMed ID: 171671
[TBL] [Abstract][Full Text] [Related]
37. Immune RNA therapy for renal cell carcinoma: survival and immunologic monitoring.
Ramming KP; deKernion JB
Ann Surg; 1977 Oct; 186(4):459-67. PubMed ID: 907390
[TBL] [Abstract][Full Text] [Related]
38. Adoptive immunotherapy of cancer: accomplishments and prospects.
Rosenberg SA
Cancer Treat Rep; 1984 Jan; 68(1):233-55. PubMed ID: 6362866
[TBL] [Abstract][Full Text] [Related]
39. In vivo effect and parallel in vitro lymphocyte-mediated tumor cytolysis after Phase I xenogeneic immune RNA treatment of patients with widespread melanoma or metastatic renal cell carcinoma.
Steele G; Wang BS; Richie J; Wilson RE; Ervin T; Yankee R; Fallon M; Mannick JA
Cancer Res; 1980 Jul; 40(7):2377-82. PubMed ID: 6155992
[No Abstract] [Full Text] [Related]
40. The gordian knot of tumour immunology.
Amlot P
Guys Hosp Rep; 1974; 123(1):43-51. PubMed ID: 4549511
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
